Cullinan Therapeutics' CLN-978 Phase 1 Data Shows Deep B-Cell Depletion, Strong Clinical Responses in SLE and RA
Summary
Cullinan Therapeutics reported detailed interim Phase 1 data for CLN-978, showing deep B-cell depletion and significant clinical responses in patients with refractory SLE and RA. Specifically, 71% of SLE patients achieved a ≥4-point hSLEDAI reduction, and 71% of RA patients improved. This builds on earlier positive initial data for CLN-978 announced on May 18th and a favorable safety profile reported on June 6th. These specific efficacy and safety numbers are a strong positive for the drug candidate, indicating its potential in autoimmune diseases and supporting its continued development. Further details or updates may emerge from the Immunology Day on June 10th.
At the time of this announcement, CGEM was trading at $14.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $830.3M. The 52-week trading range was $5.68 to $16.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.